Trastuzumab: all 614 studies that test it
Page 4 of 7. Open to participants first (88), then studies with results posted, then the rest; newest registration first within each.
- Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast CancerCompletedNCT00006110Phase 2Results posted
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast CancerCompletedNCT00004888Phase 2Results posted
- A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerActive, not recruitingNCT07386938Phase 3
- A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male ParticipantsCompletedNCT07214766Phase 1
- Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical PracticeCompletedNCT06907082Not applicable
- A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)CompletedNCT06886659Phase 1
- To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)CompletedNCT06687928Phase 1
- A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With TrastuzumabActive, not recruitingNCT06681298Phase 2
- Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract CancerActive, not recruitingNCT06178445Phase 2
- Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerActive, not recruitingNCT06109467Phase 2
- A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)Active, not recruitingNCT06100874Phase 2
- Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.CompletedNCT05997524Phase 2
- A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric CancerActive, not recruitingNCT05980481Phase 2/3
- Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male VolunteersCompletedNCT05765357Phase 1
- Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaActive, not recruitingNCT05715931Phase 2
- A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast CancerCompletedNCT05629949Phase 3
- RP-6306 in Patients With Advanced CancerCompletedNCT05605509Phase 2
- Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerTerminatedNCT05583110Phase 2
- Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerActive, not recruitingNCT05574881Phase 1/2
- BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid TumorsTerminatedNCT05555251Phase 1/2
- Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal TumorsCompletedNCT05515796Phase 2
- Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric AdenocarcinomaCompletedNCT05504720Phase 2
- Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingNCT05458674Phase 2
- Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
- A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020TerminatedNCT05385705Phase 1
- Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast CancerSuspendedNCT05378464Phase 1
- Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyWithdrawnNCT05356897Phase 2
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingNCT05323955Phase 2
- A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial CarcinomaStatus unknownNCT05318339Phase 2
- Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric CancerStatus unknownNCT05311189Phase 2
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) AdenocarcinomaTerminatedNCT05207722Phase 1/2
- Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT05193292Phase 2
- Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2
- Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma PatientsStatus unknownNCT05170256Phase 2
- Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2
- Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer PatientsSuspendedNCT05062889Phase 2
- Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2
- Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)Status unknownNCT05036005Phase 4
- Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and PyrotinibStatus unknownNCT05020964Phase 2
- A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)Active, not recruitingNCT05002127Phase 2/3
- Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa EpendymomaCompletedNCT04958486Early Phase 1
- Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic TherapyActive, not recruitingNCT04928261Phase 4
- Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)Status unknownNCT04888663Phase 1/2
- Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedNCT04789096Phase 2
- Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast CancerActive, not recruitingNCT04759248Phase 2
- Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerActive, not recruitingNCT04733118Phase 2
- Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line TherapyCompletedNCT04722133Phase 2
- A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male SubjectsCompletedNCT04670796Phase 1
- Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain MetastasisStatus unknownNCT04639271Phase 2
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal DiseaseActive, not recruitingNCT04588545Phase 1/2
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerActive, not recruitingNCT04569747Phase 2
- CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2
- TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2
- Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2
- Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)Active, not recruitingNCT04383275Phase 2
- Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2
- A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGCCompletedNCT04309578Phase 2
- Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialCompletedNCT04307329Phase 2
- Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)CompletedNCT04296162Phase 2
- Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerActive, not recruitingNCT04290793Phase 2/3
- Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT04285671Phase 1/2
- Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaCompletedNCT04281576Not applicable
- Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer PatientsCompletedNCT04253561Phase 1
- A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.Status unknownNCT04236310Phase 2
- TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryStatus unknownNCT04197687Phase 2
- Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerActive, not recruitingNCT04193059Phase 3
- Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTCTerminatedNCT04168931Phase 2
- Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast CancerStatus unknownNCT04152057Phase 1/2
- Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast CancerSuspendedNCT04120246Phase 1
- Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerStatus unknownNCT04088110Phase 2
- KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast CancerStatus unknownNCT04034823Phase 2
- Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast CancerStatus unknownNCT03994107Phase 1/2
- A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast CancerCompletedNCT03989037Phase 3
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.Status unknownNCT03947242Not applicable
- Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer PatientsStatus unknownNCT03913234Phase 1/2
- A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast CancerStatus unknownNCT03863223Phase 3
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast CancerStatus unknownNCT03847818Not applicable
- Tucatinib + Abemaciclib + Herceptin for HER2+ MBCWithdrawnNCT03846583Phase 1
- Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerActive, not recruitingNCT03803553Phase 3
- Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric CancerWithdrawnNCT03766607Phase 2
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.CompletedNCT03735966Phase 2
- DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCActive, not recruitingNCT03716180Phase 1
- Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast CancerStatus unknownNCT03698383Phase 2
- Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersTerminatedNCT03680560Phase 1
- Combination of Nanoxel and Herzuma in Salivary Duct CarcinomaStatus unknownNCT03614364Phase 2
- Trastuzumab in HER2-positive Biliary Tract CancerCompletedNCT03613168Phase 2
- Herzuma-capecitabine/Cisplatin for Gastric CancerStatus unknownNCT03588533Phase 2
- Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 StatusStatus unknownNCT03457896Phase 2
- A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing CancersActive, not recruitingNCT03448042Phase 1
- Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast CancerCompletedNCT03433313Phase 3
- Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingStatus unknownNCT03412643Phase 2
- Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast CancerActive, not recruitingNCT03368729Phase 1/2
- Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical StudyStatus unknownNCT03368131Phase 2
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)TerminatedNCT03367676Phase 2
- Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastActive, not recruitingNCT03304080Phase 1/2
- A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy SubjectsCompletedNCT03242239Phase 1
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
- Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal CancerStatus unknownNCT03225937Phase 2